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RadiosurgeryAbstract Cerebral arteriovenous malformations (AVMs) occur universally in 1.1 per 100,000 peo-
ple. These malformations are the cause of serious neurological morbidity or even death when they
bleed. AVMs are not necessarily static congenital abnormalities. They can undergo internal changes
due to angiogenesis resulting in vascular remodelling. They can even regrow after successful ther-
apy. Vascular endothelial growth factors (VEGFs) play an important role in angiogenesis. Drugs
that block the action of VEGF on vascular endothelial growth factor receptors (VEGFRs) on
the endothelial cell surface are available. This blockade causes an anti-angiogenetic effect. Anti-
angiogenic drugs are widely used as adjuvant therapy in the management of cancers because they
suppress the formation of new blood vessels required by the tumour for growth. For similar rea-
sons, they are used in the treatment of age-related macular degeneration.
The present treatment options for AVMs are surgery, embolisation and irradiation either on their
own or in combination. Irradiation with stereotactic radiosurgery (SRS) offers the advantage of
being non-invasive, but it relies on the late radiation effects to achieve its therapeutic goal of com-
plete obliteration. This latent time (1–3 years), during which the risk for a bleed remains, is an inher-
ent drawback of SRS. The histopathology of surgical specimens of post-SRS AVMs demonstrates a
role of endothelial cells in repairing the radiation damage. Suppressing their activity post SRS by a
VEGF blockade has the potential to enhance the radiation damage and hence speed up the oblit-
eration process and reduce the latent time. It is postulated that such a ‘VEGF blockade’ could be
useful as an adjuvant therapy to SRS. In addition, there is also the potential for a neo-adjuvant use,
whereby a VEGF blockade could cause regression in the size of the AVM, making deﬁnite therapy
easier. The rationale for the VEGF-blockade concept is presented and discussed.
ª 2013 Published by Elsevier Ltd. on behalf of Tehran University of Medical Sciences.D license.
ND license.
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Arteriovenous malformations (AVMs) have traditionally been
considered to be congenital with no postnatal changes during
the patient’s life. Antenatal diagnosis of the presence of cere-
bral AVMs is highly uncommon. If fully developed cerebral
AVMs were already present at birth, it might be expected that
the widespread use of computed tomography (CT) and mag-
netic resonance (MR) scans in newborns would show an inci-
dence close to that found in adolescence and adults. However
this is not the case. The postnatal development of an AVM is a
concept supported by clinical observations. Genetic and bio-
logical studies have demonstrated that an environmental trig-
ger, the so-called ‘second hit’, in addition to a genetic
predisposition can lead to the development of cerebral vascular
lesions [1]. All of the genes associated with vascular malforma-
tions of the brain to date have also known or plausible roles in
angiogenesis and vascular remodelling [2,3]. An uncontrolled
local angiogenesis process, starting after a double hit, could ex-
plain the development of AVMs into the entities as seen when
they become clinically manifest usually around the age of
4 years or later. This development during childhood and ado-
lescence is a possible explanation as to why this is the period in
life when most AVMs are diagnosed, as they rapidly develop
together with the growth of the rest of the body [4,5].
During most part of adult life they remain physiologically
active and undergo vascular remodelling on the basis of ongo-
ing neo-angiogenesis [6,7]. This can lead to further growth or,
more rarely, complete regression [8–16]. Forces that inﬂuence
this ongoing vascular remodelling are: feeding artery pressures,
venous drainage, ﬂow patterns and vascular steal [17,18]. This
remodelling is reﬂected by elevated vascular endothelial growth
factor A (VEGF-A) expression in human brain AVMs, [19,20]
elevated VEGF plasma levels [21] and active VEGF production
by AVM endothelial cells [22]. AVM endothelial cells also sig-
niﬁcantly overexpress the vascular endothelial growth factor
receptors (VEGFRs) 1 and 2, and AVM brain endothelial cells
proliferate faster and migrate more quickly [23].
The sprouting of new blood vessels or angiogenesis is a nor-
mal physiological process that is most important during embry-
onic development. This process also happens in adult life
during wound healing and during muscle development from
exercise and in the formation of collateral vessels to bypass
blocked vessels. During malignant tumour development, angi-
ogenesis plays a role in producing extra blood vessels to in-
crease the tumour blood supply [24]. This angiogenetic
process is mediated by a signal protein called VEGF. This
has actually been found to be a family of factors with the most
important one being VEGF-A [25]. Other members are pla-
centa growth factor (PGF), VEGF-B, VEGF-C and VEGF-
D. These members of the VEGF family bind to VEGFRs on
the cell surface, whereby they activate intracellular pathways.
Two such receptors have been identiﬁed, namely VEGFR-1
and VEGFR-2, of which VEGFR-2 seems to mediate almost
all of the signalling [24,25].
Present treatment options for AVMs are: (a) surgery for
those lesions that are resectable and (b) radiation therapy un-
der the form of stereotactic radiosurgery (SRS) for those le-
sions that are irresectable or when the patient refuses
surgery. Embolisation is helpful in making the surgery easier
but is not always successful on its own [26,27].SRS, by gamma knife and linear accelerator- or cyclotron-
produced charged particles, is a well-established treatment op-
tion [28]. However, lesions most effectively treated have
volumes <15 cc or a maximum diameter of ±3 cm. As the
AVM volume increases, it becomes more and more difﬁcult
to obtain an optimal balance between successful obliteration
and radiosurgical complications [29]. Even when radiosurgery
can be given with a small risk of side effects, there is always a
latent period (1–3 years) between the irradiation procedure
and the eventual obliteration. During this time the patient re-
mains at risk for a bleed, and only when the AVM is com-
pletely obliterated can the patient be considered cured [28].
The pathophysiological events after radiosurgery have been
well documented in surgical specimens post radiosurgery and
consist initially of endothelial cell death and denudation of
the vessel wall surface followed by a reactive subsequent in-
creased endothelial cell proliferation in an attempt to repair
the denudation of the vessel wall [30]. The remaining areas
of denudation then trigger a thickening of the intima layer
by proliferation of smooth muscle cells [31]. These changes
in turn lead to thrombosis of the AVM vessels. If this process
is sufﬁciently extensive it leads to complete obliteration [32,33].
The hypothesis
Current traditional methods for treating brain AVMs are
based on the concept that they are congenital and do not un-
dergo change during the patient’s life. However that is not nec-
essarily the case and there is evidence that AVMs are dynamic
entities undergoing vascular remodelling driven by angiogene-
sis. The process of angiogenesis is well understood and is stim-
ulated by activating cellular membrane receptors. Monoclonal
antibodies that block these interactions have been developed
for oncological use. They block the tumour-induced angiogen-
esis needed for tumour growth and are routinely used in the
treatment of certain cancers.
A similar VEGF blockade has potential in the management
of AVMs by suppressing the ongoing angiogenesis, a process
that is responsible not only to maintain the AVM but also to
repair the radiation-induced damage. Such a VEGF blockade
could be used as adjuvant therapy following the irradiation
procedure to suppress the repair process by proliferating endo-
thelial cells and therefore speed up the thrombotic process
responsible for obliteration. This would reduce the latent per-
iod and the time at risk for a new bleed, and in turn would
have signiﬁcant clinical and health economic implications. A
neo-adjuvant use would be aimed at suppressing the ongoing
vascular remodelling and reducing the vascular density and
to possibly make the AVM smaller and more manageable
for surgical or radiosurgical interventions.
Evaluation of the hypothesis
Drug-based anti-angiogenesis therapy is well established in
oncology [34,35].
Tumours are dependent on new blood vessel formation for
their growth and they actively promote angiogenesis by releas-
ing VEGFs in their immediate environment to achieve this. A
treatment strategy to interfere with this angiogenesis has long
been seen as a way to help in the eradication of tumours. A
variety of drugs exist that have proven anti-angiogenesis
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developed for their primary anti-angiogenetic effect, monoclo-
nal antibodies, and drugs with secondary anti-angiogenetic
effect in addition to their primary therapeutic use. The
monoclonal category has been used extensively in oncology
and their therapeutic action as well as side-effect proﬁle are
well established. A number of drugs with a secondary anti-
angiogenic effect are also in clinical use with a well-established
therapeutic and side-effect proﬁle [36–38].
One of the most commonly used anti-angiogenesis agents in
oncology is bevacizumab (Avastin), a monoclonal antibody
that binds to VEGF-A, rendering VEGF-A ineffective in its
stimulation function of the cell membrane receptor. There is
extensive clinical experience for a variety of cancers with this
drug. Bevacizumab is Food and Drug Administration (FDA)-
approved for the treatment of: (a) metastatic colorectal cancer,
(b) non-small cell lung cancer, (c) glioblastoma and (d) meta-
static renal cell carcinoma.
In addition, it is used in ophthalmology for age-related
macular degeneration [39].
The proliferative activity of endothelial cells in AVMs is
also governed by angiogenesis factors acting on their cell mem-
brane receptors, and blocking this interaction with anti-angio-
genesis drugs should therefore have therapeutic potential in the
management of AVMs. This could be called a VEGF blockade
[40]. If the post-radiation increased endothelial cell prolifera-
tion in reaction to the radiation damage could be blocked, then
larger areas of denudation would remain. This would in turn
be a more extensive trigger for thrombosis in the AVM vessels.
The concept of attempting to improve the therapeutic ben-
eﬁt from radiosurgery is not new [41]. Sims and Plowman [42]
tried this by protecting the normal surrounding brain from the
radiation effects. Their radiosurgical treatment of large AVMs
explored the use of gamma linolenic acid (GLA), which has a
protective effect on normal brain. They found that GLA did
not improve the therapeutic ratio as it also offered protection
for the AVM against the effect of the radiation.
Adjuvant use post radiosurgery
Bevacizumab only has a suppressive effect on angiogenesis,
which is lost once the drug is stopped as seen in tumour
angiogenesis suppression. Therefore, a continuous blockade
starting soon after radiosurgery and achieved by regular
administration of bevacizumab 10 mg kg1 intravenous infu-
sion (IVI) every 2 weeks would be required until obliteration
is complete [35]. This is also the way bevacizumab is used in
oncology, whereby angiogenesis is blocked for many
months/years [43–45]. The side-effect proﬁle of such long-
term administration is well established. Most common
adverse effects are: (a) hypertension, (b) gastrointestinal
perforation, (c) wound-healing complications (traumatic
and surgical) and (d) haemorrhage in the form of haemopt-
ysis, gastrointestinal bleeding, central nervous system (CNS)
haemorrhage and vaginal bleeding [34,35].
The safety and effectiveness of bevacizumab have not been
established in paediatric oncology patients [35]. Because long-
term use of a VEGF blockade could hamper ﬁnal development
of organs in the body of patients who are still growing, its use
in children and adolescents should only be considered once
sufﬁcient clinical data from adult studies have been obtained.The possible outcomes of such an intervention could be to:
(a) speed up the obliteration process and hence reduce the per-
iod at risk for bleeding, (b) improve the overall obliteration
rate for radiosurgery, (c) achieve the same obliteration rate
with lower radiation doses and (d) a combination of these
factors.
The effect of bevacizumab on AVMs has been demon-
strated in an animal model. Walker et al. [46] showed that
VEGF antagonism by bevacizumab reduced the vessel density
in AVMs in the adult mouse brain.
Bevacizumab has also been shown to have radiation-sensi-
tising properties when used in combination with radiation [47].
Although this is desirable in terms of the radiation effects on
the AVM itself, there is an as-yet not-quantiﬁed and unknown
risk of increased damage to normal blood vessels in the vicinity
of the AVM if these would be exposed to low doses of radia-
tion in combination with bevacizumab. Hence at this stage
the safest use would be post radiosurgery [48].
Monitoring the effect of a VEGF blockade after radiosur-
gery would be essentially the same as after radiosurgery alone,
whereby regular radiological imaging is done to observe how
quickly and when the complete obliteration has occurred.
Although VEGF plasma levels can be measured in patients
and are signiﬁcantly elevated in untreated AVM patients com-
pared to normal individuals [21], their role in monitoring the
VEGF blockade would have to be investigated.
Neo-adjuvant use
A VEGF blockade could have therapeutic implications in the
sense that it could possibly shrink the size of the AVM making
neurosurgical removal easier. A reduction in size would also
make SRS safer, because the risk of developing symptomatic
radiation injury after radiosurgery is related to lesion diameter
and volume.
The inﬂuence on the symptoms due to the AVM’s presence
such as headaches and epilepsy is speculative, but the possibil-
ity exists that these might be alleviated by a VEGF blockade.
Discussion
Radiosurgery is a frequently used treatment option. A meta-
analysis in 2011 by van Beijum et al. [49] looking at a total
population of 13,698 patients diagnosed with an intracranial
AVM, found that 9436 (69%) of the patients were managed
by radiosurgery. The post-radiosurgery intracranial haemor-
rhage rate for this group was 1.7 per 100 person years. Other
studies have reported post-radiosurgery annual haemorrhage
risks ranging from 1.14% to 2.2%, [50–53] and an overall per-
manent morbidity of a re-haemorrhage from 30% to 40% with
a mortality rate between 9% and 12.5% [54,55]. If indeed the
post-radiosurgery VEGF blockade reduces the latent time and
hence shortens the period at risk for a haemorrhage, this
would have signiﬁcant clinical and health economic
implications.
Radiosurgical AVM obliteration is dose dependent with
higher doses giving an earlier and higher obliteration rate.
Unfortunately higher doses also mean higher complication
rates, and hence any radiation dose reduction that would be
possible without negatively affecting the obliteration rate
would improve the therapeutic ratio.
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peutic effect it would subsequently become possible to investi-
gate lowering the radiation dose and still achieve the same
obliteration rate. It would also open the way for a neo-adju-
vant use to facilitate the use of surgery or SRS.
Conclusion
Based on the concept that AVMs are dynamic entities with
ongoing vascular remodelling driven by angiogenesis, and
the fact that repair of radiation damage is also related to angi-
ogenesis, the use of anti-angiogenic drugs has theoretical ther-
apeutic potential in the overall management of this disease and
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